Ignite Creation Date:
2025-12-24 @ 6:52 PM
Ignite Modification Date:
2025-12-29 @ 12:43 AM
Study NCT ID:
NCT04519957
Status:
COMPLETED
Last Update Posted:
2022-09-22
First Post:
2020-08-13
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'submissionTracking': {'submissionInfos': [{'resetDate': '2024-09-05', 'releaseDate': '2024-04-09'}], 'estimatedResultsFirstSubmitDate': '2024-04-09'}}, 'conditionBrowseModule': {'meshes': [{'id': 'D061218', 'term': 'Depressive Disorder, Treatment-Resistant'}], 'ancestors': [{'id': 'D003866', 'term': 'Depressive Disorder'}, {'id': 'D019964', 'term': 'Mood Disorders'}, {'id': 'D001523', 'term': 'Mental Disorders'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'ECOLOGIC_OR_COMMUNITY'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 66}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2020-07-20', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2022-09', 'completionDateStruct': {'date': '2022-08-11', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2022-09-21', 'studyFirstSubmitDate': '2020-08-13', 'studyFirstSubmitQcDate': '2020-08-17', 'lastUpdatePostDateStruct': {'date': '2022-09-22', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2020-08-20', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-08-11', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Long-term efficacy of psilocybin', 'timeFrame': 'up to 52 weeks', 'description': 'Use of new antidepressant treatment, hospitalisations for depression, suicidality, and depressive severity rated using the Montgomery and Asberg Depression Rating Scale (MADRS)'}], 'secondaryOutcomes': [{'measure': 'Response, sustained response, remission and change in depression severity', 'timeFrame': 'Up to 52 weeks', 'description': 'Montgomery Asberg Depression Rating Scale (MADRS)'}, {'measure': 'Psychosocial functioning and to predict durability of response to antidepressant treatment', 'timeFrame': 'up to 52 weeks', 'description': 'Work and Social Adjustment Scale (WSAS) score change from Baseline of the prior study'}, {'measure': 'Functional impairment in work/school, social life, and family life.', 'timeFrame': 'Up to 52 weeks', 'description': 'Sheehan Disability Scale (SDS) score change from Baseline of the prior study'}, {'measure': 'Safety of Psilocybin', 'timeFrame': 'Up to 52 weeks', 'description': 'Incidence and severity of Adverse Events (AEs) and Seroius Adverse Events (SAEs)'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Treatment Resistant Depression']}, 'referencesModule': {'references': [{'pmid': '40047545', 'type': 'DERIVED', 'citation': 'Goodwin GM, Nowakowska A, Atli M, Dunlop BW, Feifel D, Hellerstein DJ, Marwood L, Shabir Z, Mistry S, Stansfield SC, Teoh E, Tsai J, Young MB, Malievskaia E. Results From a Long-Term Observational Follow-Up Study of a Single Dose of Psilocybin for a Treatment-Resistant Episode of Major Depressive Disorder. J Clin Psychiatry. 2025 Mar 3;86(1):24m15449. doi: 10.4088/JCP.24m15449.'}]}, 'descriptionModule': {'briefSummary': 'The primary objective of this study is to assess the long-term efficacy of psilocybin with respect to use of new antidepressant treatment, hospitalisations for depression, suicidality, and depressive severity rated using the Montgomery and Asberg Depression Rating Scale (MADRS) over a total of 52 weeks (compared across the 1 mg, 10 mg and 25 mg psilocybin groups from COMP 001).', 'detailedDescription': 'In this present study (COMP 004), the aim is to follow up participants from COMP 001 and COMP 003 in a long-term follow up study, with both remote and digital assessments, to explore the long term efficacy and safety of the three different doses of psilocybin (1 mg, 10 mg, and 25 mg) administered to patients with TRD as a monotherapy in COMP 001 and 25 mg psilocybin administered as an adjunct to an SSRI in COMP 003. Patients previously treated in COMP001 will be followed for approximately 40 weeks and patients previosuly treated in COMP003 will be followed for approximately 49 weeks giving a total follow up period of 52 weeks from psilocybin dosing.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '55 Years', 'minimumAge': '18 Years', 'samplingMethod': 'PROBABILITY_SAMPLE', 'studyPopulation': 'TRD patients who completed COMP001 or COMP003', 'eligibilityCriteria': 'Inclusion Criteria:\n\nSigned ICF Each participant having completed the final study visit of either COMP 001 or COMP 003 Ability to complete all protocol required assessment tools (including having access to the internet in order to complete the digital assessments) without any assistance or alteration to the copyrighted assessments, and to comply with all study visits\n\nExclusion Criteria:\n\nSubject has any condition, for which in the opinion of the investigator, participation would not be in the interest of the subject eg participation could compromise the wellbeing of the participant or prevent, limit, or confound the protocol-specified assessments'}, 'identificationModule': {'nctId': 'NCT04519957', 'briefTitle': 'Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)', 'organization': {'class': 'INDUSTRY', 'fullName': 'COMPASS Pathways'}, 'officialTitle': 'Multicentre Study To Assess Safety And Efficacy Of Psilocybin In Patients With Treatment-Resistant Depression Following Completion Of COMP 001 And COMP 003 Trials (P-TRD LTFU)', 'orgStudyIdInfo': {'id': 'COMP004'}}, 'contactsLocationsModule': {'locations': [{'zip': '92037', 'city': 'La Jolla', 'state': 'California', 'country': 'United States', 'facility': 'Kadima Neuropsychiatry Institute', 'geoPoint': {'lat': 32.84727, 'lon': -117.2742}}, {'zip': '92093', 'city': 'San Diego', 'state': 'California', 'country': 'United States', 'facility': 'Altman Clinical and Translational Research Institute, University of California', 'geoPoint': {'lat': 32.71571, 'lon': -117.16472}}, {'zip': '30329', 'city': 'Atlanta', 'state': 'Georgia', 'country': 'United States', 'facility': 'Mood and Anxiety Disorders Program Emory University School of Medicine', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'zip': '77054', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'UT Center of Excellence on Mood Disorders, University of Texas Health Science Center', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'city': 'Klecany', 'country': 'Czechia', 'facility': 'National Institute of Mental Health Czech Republic', 'geoPoint': {'lat': 50.17599, 'lon': 14.41148}}, {'city': 'Dublin', 'country': 'Ireland', 'facility': 'Sheaf House, Tallaght Hospital', 'geoPoint': {'lat': 53.33306, 'lon': -6.24889}}, {'city': 'Groningen', 'country': 'Netherlands', 'facility': 'Groningen University Medical Centre', 'geoPoint': {'lat': 53.21917, 'lon': 6.56667}}, {'city': 'London', 'country': 'United Kingdom', 'facility': 'Kings College London, Institute of Psychiatry, Psychology and Neurology', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'COMPASS Pathways', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}, 'annotationSection': {'annotationModule': {'unpostedAnnotation': {'unpostedEvents': [{'date': '2024-04-09', 'type': 'RELEASE'}, {'date': '2024-09-05', 'type': 'RESET'}], 'unpostedResponsibleParty': 'COMPASS Pathways'}}}}